Skip to main content
Log in

Brain natriuretic peptide as a marker of cardiac toxicity in patients with multiple sclerosis treated with mitoxantrone

  • LETTER TO THE EDITORS
  • Published:
Journal of Neurology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Weber M, Hamm C (2003) Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart 92:843–849

    Article  Google Scholar 

  2. Battaglia M, Pewsner D, Jűni P, Egger M, Bucher HC, Bachmann LM (2006) Accuracy of B-type natriuretic peptide tests to exclude congestive heart failure. Systematic review of test accuracy studies. Arch Intern Med 166:1073–1080

    Article  PubMed  Google Scholar 

  3. Maisel AS, Krishnaswamy P, Nowak RM, et al. Breathing Not Properly Multinational Study Investigators (2002) Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347:161–167

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to P. Bertora.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bertora, P., Torzillo, D., Baldi, G. et al. Brain natriuretic peptide as a marker of cardiac toxicity in patients with multiple sclerosis treated with mitoxantrone. J Neurol 255, 140–141 (2008). https://doi.org/10.1007/s00415-007-0689-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-007-0689-2

Keywords

Navigation